Evaluation of the safety and efficacy of surgery for radio-recurrent prostate cancer: a systematic review and meta-analysis

放射治疗后复发性前列腺癌手术安全性和有效性评价:系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Surgery plays a critical role in managing radio-recurrent prostate cancer (PCa). This study aims to comprehensively review its effectiveness and associated severe complications. METHODS: A thorough review of PubMed and EMBASE databases up to July 2024 was conducted, focusing on recurrence-free survival (RFS) with salvage surgery across various subgroups. Severe complications were also assessed using the Clavien-Dindo Scale (CDS). Survival curves were reconstructed using WebPlotDigitizer and a newly developed shiny application. RESULTS: Forty-four studies were included, with 17 papers (2056 patients) contributing to survival curve reconstruction. Among 1654 patients treated with salvage surgery after eliminating duplicate cases, the median RFS was 63.9 months, with 2-, 3-, and 5-year rates of 65.6%, 59.3%, and 51.2%, respectively. Factors associated with better RFS included robot-assisted surgery [hazard ratio (HR):1.49, p < 0.001], lower rates of seminal vesicle invasion (SVI) (HR: 0.75, p = 0.006) and lymph node involvement (LNI) (HR: 0.74, p = 0.006), higher proportion of adjuvant androgen deprivation therapy (ADT) (HR: 2.96, p < 0.001), and higher values of pathological Gleason scores (GS) (≤7/≥8) (HR:1.30, p < 0.001). Severe complications (grade ≥ IIIa) occurred in 404 out of 2537 patients (15.9%, 95% CI: 14.5 to 17.4). CONCLUSIONS: This study comprehensively assesses complications and conducts a pooled analysis of RFS for salvage surgery in radio-recurrent PCa. Robot-assisted surgery, lower rates of SVI and LNI, adjuvant ADT, and higher proportions of pathological GS ≤7 appear promising as prognostic factors for RFS. However, confirming these findings will necessitate randomized controlled trials due to low levels of evidence and study heterogeneity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。